Published in J Pathol on December 09, 2011
Specific bone cells produce DLL4 to generate thymus-seeding progenitors from bone marrow. J Exp Med (2015) 1.91
Chemokine receptor-specific antibodies in cancer immunotherapy: achievements and challenges. Front Immunol (2015) 0.91
Notch1-induced T cell leukemia can be potentiated by microenvironmental cues in the spleen. J Hematol Oncol (2014) 0.83
Notch signaling deregulation in multiple myeloma: A rational molecular target. Oncotarget (2015) 0.81
CC chemokine receptor 5: the interface of host immunity and cancer. Dis Markers (2014) 0.79
Repression of Ccr9 transcription in mouse T lymphocyte progenitors by the Notch signaling pathway. J Immunol (2015) 0.77
CCR9 in cancer: oncogenic role and therapeutic targeting. J Hematol Oncol (2016) 0.77
Antitumor effects of a monoclonal antibody to human CCR9 in leukemia cell xenografts. MAbs (2014) 0.76
Multiple myeloma-derived Jagged ligands increases autocrine and paracrine interleukin-6 expression in bone marrow niche. Oncotarget (2016) 0.76
Lack of Correlation Between the CCR5-Δ32 Mutation and Acute Myeloid Leukemia in Iranian Patients. Indian J Hematol Blood Transfus (2014) 0.75
Absence of Association between CCR5 rs333 Polymorphism and Childhood Acute Lymphoblastic Leukemia. Adv Hematol (2014) 0.75
Interplay between CCR7 and Notch1 axes promotes stemness in MMTV-PyMT mammary cancer cells. Mol Cancer (2017) 0.75
The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol (2004) 19.38
Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol (2002) 17.85
Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet (2008) 12.59
Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet (2009) 12.19
Macrophage activation and polarization. Front Biosci (2008) 11.17
Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol (2006) 9.82
Macrophage polarization comes of age. Immunity (2005) 5.67
Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med (2014) 5.47
Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med (2014) 4.94
Macrophage plasticity and polarization in tissue repair and remodelling. J Pathol (2012) 4.30
Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nat Med (2002) 4.04
Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood (2003) 3.88
Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease. N Engl J Med (2016) 3.88
Transcriptional profiling reveals complex regulation of the monocyte IL-1 beta system by IL-13. J Immunol (2005) 3.87
Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease. Gut (2011) 3.81
The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J Clin Invest (2009) 3.34
Induction and regulatory function of miR-9 in human monocytes and neutrophils exposed to proinflammatory signals. Proc Natl Acad Sci U S A (2009) 3.27
Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. Cancer Res (2007) 3.19
Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother (2007) 3.16
Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica (2005) 3.11
New vistas on macrophage differentiation and activation. Eur J Immunol (2007) 2.99
Tuning inflammation and immunity by chemokine sequestration: decoys and more. Nat Rev Immunol (2006) 2.92
Factors associated with outcomes of unrelated cord blood transplant: guidelines for donor choice. Exp Hematol (2004) 2.81
Macrophage diversity and polarization in atherosclerosis: a question of balance. Arterioscler Thromb Vasc Biol (2009) 2.80
Arginase-1 and Ym1 are markers for murine, but not human, alternatively activated myeloid cells. J Immunol (2005) 2.75
Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother (2002) 2.65
Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial. Blood (2004) 2.62
Head and neck squamous cell cancer and the human papillomavirus: summary of a National Cancer Institute State of the Science Meeting, November 9-10, 2008, Washington, D.C. Head Neck (2009) 2.59
Imatinib for refractory chronic graft-versus-host disease with fibrotic features. Blood (2009) 2.51
Clinical features, long-term follow-up and outcome of a large cohort of patients with Chronic Granulomatous Disease: an Italian multicenter study. Clin Immunol (2007) 2.38
The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. Blood (2008) 2.35
Survival after T cell-depleted haploidentical stem cell transplantation is improved using the mother as donor. Blood (2008) 2.34
Mutations in ANKRD26 are responsible for a frequent form of inherited thrombocytopenia: analysis of 78 patients from 21 families. Blood (2011) 2.29
Congenital amegakaryocytic thrombocytopenia: clinical and biological consequences of five novel mutations. Haematologica (2007) 2.23
Atypical features of familial hemophagocytic lymphohistiocytosis. Blood (2004) 2.21
Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation. Hum Immunol (2009) 2.19
Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood (2011) 2.18
Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and coronary artery disease in 19 case-control studies. J Am Coll Cardiol (2010) 2.17
Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. Blood (2009) 2.15
Genetic programs expressed in resting and IL-4 alternatively activated mouse and human macrophages: similarities and differences. Blood (2013) 2.14
Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy. Blood (2013) 2.12
International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol Rev (2013) 2.11
Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. J Clin Oncol (2005) 2.10
Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. Proc Natl Acad Sci U S A (2004) 2.06
Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica (2002) 1.91
Chemokines and chemokine receptors: an overview. Front Biosci (Landmark Ed) (2009) 1.87
Role of c-MYC in alternative activation of human macrophages and tumor-associated macrophage biology. Blood (2011) 1.84
The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease. Blood (2005) 1.80
Phenotypic and functional heterogeneity of human NK cells developing after umbilical cord blood transplantation: a role for human cytomegalovirus? Blood (2011) 1.78
Donor/recipient mixed chimerism does not predict graft failure in children with beta-thalassemia given an allogeneic cord blood transplant from an HLA-identical sibling. Haematologica (2008) 1.78
Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection. Blood (2011) 1.76
Mesenchymal stromal cells. Ann N Y Acad Sci (2009) 1.76
The chemokine system in cancer biology and therapy. Cytokine Growth Factor Rev (2009) 1.75
Inherited perforin and Fas mutations in a patient with autoimmune lymphoproliferative syndrome and lymphoma. N Engl J Med (2004) 1.72
FAM20: an evolutionarily conserved family of secreted proteins expressed in hematopoietic cells. BMC Genomics (2005) 1.70
Expression of sperm protein 17 (Sp17) in ovarian cancer. Int J Cancer (2004) 1.70
Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA Working Party. Haematologica (2010) 1.68
Functional specialization of human circulating CD16 and CD1c myeloid dendritic-cell subsets. Blood (2007) 1.67
Differential regulation of iron homeostasis during human macrophage polarized activation. Eur J Immunol (2010) 1.64
Haematopoietic stem cell transplantation in haemophagocytic lymphohistiocytosis. Br J Haematol (2005) 1.64
Differential regulation of chemokine production by Fcgamma receptor engagement in human monocytes: association of CCL1 with a distinct form of M2 monocyte activation (M2b, Type 2). J Leukoc Biol (2006) 1.63
Unique role of junctional adhesion molecule-a in maintaining mucosal homeostasis in inflammatory bowel disease. Gastroenterology (2008) 1.62
Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood (2003) 1.58
Human mesenchymal stem cells and cyclosporin a exert a synergistic suppressive effect on in vitro activation of alloantigen-specific cytotoxic lymphocytes. Biol Blood Marrow Transplant (2005) 1.58
Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia. J Clin Oncol (2005) 1.58
Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation. Blood (2010) 1.56
Ethical reappraisal of 15 years of cord-blood transplantation. Lancet (2003) 1.55
A proportion of patients with lymphoma may harbor mutations of the perforin gene. Blood (2005) 1.54
Feasibility and safety of adoptive immunotherapy with ex vivo-generated autologous, cytotoxic T lymphocytes in patients with solid tumor. Cytotherapy (2011) 1.54
Cutting edge: scavenging of inflammatory CC chemokines by the promiscuous putatively silent chemokine receptor D6. J Immunol (2003) 1.52
Rising antigenemia levels may be misleading in pre-emptive therapy of human cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients. Haematologica (2005) 1.51
Response to mycophenolate mofetil therapy in refractory chronic graft-versus-host disease. Haematologica (2003) 1.51
Unrelated cord blood transplantation for childhood acute myeloid leukemia: a Eurocord Group analysis. Blood (2003) 1.49
Human NK cells: from HLA class I-specific killer Ig-like receptors to the therapy of acute leukemias. Immunol Rev (2008) 1.47
The novel RASSF6 and RASSF10 candidate tumour suppressor genes are frequently epigenetically inactivated in childhood leukaemias. Mol Cancer (2009) 1.44
SAP controls the cytolytic activity of CD8+ T cells against EBV-infected cells. Blood (2005) 1.44
Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor. Cancer Res (2005) 1.44
Chemokines in the recruitment and shaping of the leukocyte infiltrate of tumors. Semin Cancer Biol (2004) 1.43
Congenital aggressive variant of Langerhans cells histiocytosis with CD56+/E-Cadherin- phenotype. Pediatr Blood Cancer (2009) 1.42
Treatment with short-term, high-dose cyclosporin A in children with refractory chronic idiopathic thrombocytopenic purpura. Br J Haematol (2003) 1.42
Human hepatic stellate cells are liver-resident antigen-presenting cells. Hepatology (2011) 1.42